Market Overview

Johnson & Johnson Shares Might Break Lower Before They Break Out

Share:
Johnson & Johnson Shares Might Break Lower Before They Break Out

Just a day after Credit Suisse reinstated an Outperform rating on Johnson & Johnson (NYSE: JNJ) based on future gain from Actelion, BTIG and Atlantic Equities downgraded the stock from Neutral to Sell and Underweight, respectively, for nearly the opposite reason.

Atlantic Equities: Weak Setup For 2018

Despite the downgrade, Atlantic Equities’ Steve Chesney bumped up his price target by a dollar, from $112 to $113.

The analyst recognizes that Johnson & Johnson has several therapies moving through the pipeline on target, but believes they will be insufficient to drive significant growth.

“We see only 2–3 credible, near-term, [greater-than] $1 billion opportunities,” said Chesney.

Chesney also thinks investors are too dismissive competitor data, which detracts from a bullish view in the near term.

Fundamental weakness could be covered up by gains from Actelion in the second half of 2017, but will likely be revealed in early 2018 regardless.

Overall, headwinds moving into fiscal 2018 seem to be brewing, and Chesney sees only single-digit pharmaceuticals growth ahead.

tipranks.png

BTIG: ‘Correction Is Overdue’

BTIG analyst Dane Leone set a $110 price target on the stock, representing a 20-percent downside from Thursday’s close.

“Our review of the Pharmaceuticals segment suggests lackluster sales growth through 2021,” said Leone.

The analyst’s model considers expected “blockbuster” drug launches and acquired growth through Actelion, but ultimately concluded with only 3.75 percent growth, significantly less than the company’s projected 5+ percent.

The model also sees declining growth rates year-over-year through 2021.

Regarding Actelion, Leone expects “little synergy, and near zero upside from current consensus estimates.”

tipranks.png

Keep up with analyst coverage in real time with Benzinga Pro.

Related Links:

The Market In 5 Minutes

Following Q2 Beat, Sarepta Has A Key Catalyst Coming In Q4

_______
Image Credit: By Raysonho @ Open Grid Scheduler / Grid Engine - Own work, CC0, via Wikimedia Commons

Latest Ratings for JNJ

DateFirmActionFromTo
Jul 2020Independent ResearchUpgradesHoldBuy
Jul 2020Raymond JamesMaintainsOutperform
Jul 2020CitigroupMaintainsBuy

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: Analyst Color Long Ideas News Short Ideas Upgrades Downgrades Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
BIIBRBC CapitalMaintains277.0
RLICompass PointInitiates Coverage On90.0
CSCOWolfe ResearchDowngrades42.0
NKEBarclaysMaintains132.0
GILDRBC CapitalMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com